These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22442351)

  • 1. A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer.
    Elvington M; Huang Y; Morgan BP; Qiao F; van Rooijen N; Atkinson C; Tomlinson S
    Blood; 2012 Jun; 119(25):6043-51. PubMed ID: 22442351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
    Imai M; Ohta R; Varela JC; Song H; Tomlinson S
    Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer.
    Imai M; Landen C; Ohta R; Cheung NK; Tomlinson S
    Cancer Res; 2005 Nov; 65(22):10562-8. PubMed ID: 16288049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
    Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
    Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice.
    Boross P; Jansen JH; van Tetering G; Nederend M; Brandsma A; Meyer S; Torfs E; van den Ham HJ; Meulenbroek L; de Haij S; Leusen JH
    Immunol Lett; 2014 Aug; 160(2):151-7. PubMed ID: 24613852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model.
    Wang SY; Veeramani S; Racila E; Cagley J; Fritzinger DC; Vogel CW; St John W; Weiner GJ
    Blood; 2009 Dec; 114(26):5322-30. PubMed ID: 19805620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activation determines the therapeutic activity of rituximab in vivo.
    Di Gaetano N; Cittera E; Nota R; Vecchi A; Grieco V; Scanziani E; Botto M; Introna M; Golay J
    J Immunol; 2003 Aug; 171(3):1581-7. PubMed ID: 12874252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
    Helfand SC; Hank JA; Gan J; Sondel PM
    Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
    Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
    J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of monoclonal antibody affinity in tumor immunotherapy evaluated in in vivo models for minimal residual disease.
    Velders MP; van Rhijn CM; Cornelissen IM; van Muijen GN; Briaire IH; Dohlsten M; Fleuren GJ; Warnaar SO; Litvinov SV
    J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):245-56. PubMed ID: 8877719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice.
    Banda NK; Levitt B; Glogowska MJ; Thurman JM; Takahashi K; Stahl GL; Tomlinson S; Arend WP; Holers VM
    J Immunol; 2009 Nov; 183(9):5928-37. PubMed ID: 19828624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
    Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
    Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nude mouse model to study passive humoral immunotherapy directed against B16 F10 murine melanoma.
    Shrayer D; Bogaars H; Gersten D; Hearing V; Maizel A; Wanebo H
    J Surg Oncol; 1994 Sep; 57(1):50-6. PubMed ID: 8065154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease.
    Kulik L; Hewitt FB; Willis VC; Rodriguez R; Tomlinson S; Holers VM
    Mol Immunol; 2015 Feb; 63(2):479-88. PubMed ID: 25457881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.
    Minard-Colin V; Xiu Y; Poe JC; Horikawa M; Magro CM; Hamaguchi Y; Haas KM; Tedder TF
    Blood; 2008 Aug; 112(4):1205-13. PubMed ID: 18495955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
    Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
    Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Delivery of TNF Potentiates the Antibody-Dependent Cell-Mediated Cytotoxicity of an Anti-Melanoma Immunoglobulin.
    Murer P; Kiefer JD; Plüss L; Matasci M; Blümich SL; Stringhini M; Neri D
    J Invest Dermatol; 2019 Jun; 139(6):1339-1348. PubMed ID: 30543899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
    Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
    Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membrane-bound complement regulatory proteins inhibit complement activation by an immunotherapeutic mAb in a syngeneic rat colorectal cancer model.
    Gelderman KA; Hakulinen J; Hagenaars M; Kuppen PJ; Meri S; Gorter A
    Mol Immunol; 2003 Sep; 40(1):13-23. PubMed ID: 12909127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.